Cargando…

Variants Identified in a GWAS Meta-Analysis for Blood Lipids Are Associated with the Lipid Response to Fenofibrate

A recent large-scale meta-analysis of genome-wide studies has identified 95 loci, 59 of them novel, as statistically significant predictors of blood lipid traits; we tested whether the same loci explain the observed heterogeneity in response to lipid-lowering therapy with fenofibrate. Using data fro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aslibekyan, Stella, Goodarzi, Mark O., Frazier-Wood, Alexis C., Yan, Xiaofei, Irvin, Marguerite R., Kim, Eric, Tiwari, Hemant K., Guo, Xiuqing, Straka, Robert J., Taylor, Kent D., Tsai, Michael Y., Hopkins, Paul N., Korenman, Stanley G., Borecki, Ingrid B., Chen, Yii-Der I., Ordovas, Jose M., Rotter, Jerome I., Arnett, Donna K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3485381/ https://www.ncbi.nlm.nih.gov/pubmed/23119086 http://dx.doi.org/10.1371/journal.pone.0048663

Ejemplares similares

Lipid changes due to fenofibrate treatment are not associated with changes in DNA methylation patterns in the GOLDN study
por: Das, Mithun, et al.
Publicado: (2015)

Genetic Risk Scores Associated with Baseline Lipoprotein Subfraction Concentrations Do Not Associate with Their Responses to Fenofibrate
por: Frazier-Wood, Alexis C., et al.
Publicado: (2014)

The PPAR Alpha gene is associated with triglyceride, low-density cholesterol, and inflammation marker response to fenofibrate intervention: The GOLDN Study
por: Frazier-Wood, A.C., et al.
Publicado: (2012)

An Exome-Wide Sequencing Study of the GOLDN Cohort Reveals Novel Associations of Coding Variants and Fasting Plasma Lipids
por: Geng, Xin, et al.
Publicado: (2019)

Genomics of Post-Prandial Lipidomic Phenotypes in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study
por: Irvin, Marguerite R., et al.
Publicado: (2014)

Epigenome-Wide Association Study of Fasting Measures of Glucose, Insulin, and HOMA-IR in the Genetics of Lipid Lowering Drugs and Diet Network Study
por: Hidalgo, Bertha, et al.
Publicado: (2014)

TCF7L2 polymorphisms and inflammatory markers before and after treatment with fenofibrate
por: Kabagambe, Edmond K, et al.
Publicado: (2009)

Heritable DNA Methylation in CD4(+) Cells among Complex Families Displays Genetic and Non-Genetic Effects
por: Day, Kenneth, et al.
Publicado: (2016)

Clustering by Plasma Lipoprotein Profile Reveals Two Distinct Subgroups with Positive Lipid Response to Fenofibrate Therapy
por: van Bochove, Kees, et al.
Publicado: (2012)

Association of DNA Methylation at CPT1A Locus with Metabolic Syndrome in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study
por: Das, Mithun, et al.
Publicado: (2016)

Insulin Clearance Is Associated with Hepatic Lipase Activity and Lipid and Adiposity Traits in Mexican Americans
por: Labadzhyan, Artak, et al.
Publicado: (2016)

Genetic variants modify the effect of age on APOE methylation in the Genetics of Lipid Lowering Drugs and Diet Network study
por: Ma, Yiyi, et al.
Publicado: (2015)

Rosiglitazone and Fenofibrate Additive Effects on Lipids
por: Slim, Ahmad, et al.
Publicado: (2011)

Preliminary Evidence for an Association between LRP-1 Genotype and Body Mass Index in Humans
por: Frazier-Wood, Alexis C., et al.
Publicado: (2012)

Disentangling associations between DNA methylation and blood lipids: a Mendelian randomization approach
por: Sayols-Baixeras, Sergi, et al.
Publicado: (2018)

The association between LRP1 and chylomicron uptake after the ingestion of a high-fat meal
por: Frazier-Wood, AC, et al.
Publicado: (2012)

A clustering analysis of lipoprotein diameters in the metabolic syndrome
por: Frazier-Wood, Alexis C, et al.
Publicado: (2011)

Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial
por: Reyes-Soffer, Gissette, et al.
Publicado: (2013)

Preparation and Evaluation of Lipid-Based Liquid Crystalline Formulation of Fenofibrate
por: Kazemi, Moloud, et al.
Publicado: (2018)

High-fat meal effect on LDL, HDL, and VLDL particle size and number in the Genetics of Lipid-Lowering drugs and diet network (GOLDN): an interventional study
por: Wojczynski, Mary K, et al.
Publicado: (2011)

Data for GAW20: genome-wide DNA sequence variation and epigenome-wide DNA methylation before and after fenofibrate treatment in a family study of metabolic phenotypes
por: Aslibekyan, Stella, et al.
Publicado: (2018)

Epigenome-wide association study of metabolic syndrome in African-American adults
por: Akinyemiju, Tomi, et al.
Publicado: (2018)

Genomics of Postprandial Lipidomics in the Genetics of Lipid-Lowering Drugs and Diet Network Study
por: Irvin, Marguerite R., et al.
Publicado: (2021)

PCSK9 variation and association with blood pressure in African Americans: preliminary findings from the HyperGEN and REGARDS studies
por: Tran, Ngan T., et al.
Publicado: (2015)

Porous Nanostructure, Lipid Composition, and Degree of Drug Supersaturation Modulate In Vitro Fenofibrate Solubilization in Silica-Lipid Hybrids
por: Almasri, Ruba, et al.
Publicado: (2020)

Metabolic and inflammatory biomarkers are associated with epigenetic aging acceleration estimates in the GOLDN study
por: Irvin, Marguerite R., et al.
Publicado: (2018)

Fenofibrate: a novel formulation (Triglide™) in the treatment of lipid disorders: a review
por: Tziomalos, Konstantinos, et al.
Publicado: (2006)

Lipoprotein Lipase S447X variant associated with VLDL, LDL and HDL diameter clustering in the MetS
por: Wood, Alexis C, et al.
Publicado: (2011)

Epigenome-wide study identifies novel methylation loci associated with body mass index and waist circumference
por: Aslibekyan, Stella, et al.
Publicado: (2015)

A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination
por: Filippatos, Theodosios D.
Publicado: (2012)

A Randomized Trial of Lipid Metabolism Modulation with Fenofibrate for Acute Coronavirus Disease 2019
por: Chirinos, Julio, et al.
Publicado: (2022)

Pairwise effects between lipid GWAS genes modulate lipid plasma levels and cellular uptake
por: Zimoń, Magdalena, et al.
Publicado: (2021)

Epigenome-wide association study of triglyceride postprandial responses to a high-fat dietary challenge
por: Lai, Chao-Qiang, et al.
Publicado: (2016)

Pharmacogenetics of lipid diseases
por: Ordovas, Jose M
Publicado: (2004)

Supersaturation and Solubilization upon In Vitro Digestion of Fenofibrate Type I Lipid Formulations: Effect of Droplet Size, Surfactant Concentration and Lipid Type
por: Katev, Vladimir, et al.
Publicado: (2021)

Body Adiposity Index versus Body Mass Index and Other Anthropometric Traits as Correlates of Cardiometabolic Risk Factors
por: Lichtash, Charlene T., et al.
Publicado: (2013)

Physical Activity Associations with Bone Mineral Density and Modification by Metabolic Traits
por: Buttan, Anshu, et al.
Publicado: (2020)

Achievement of Lipid Targets with the Combination of Rosuvastatin and Fenofibric Acid in Patients with Type 2 Diabetes Mellitus
por: Rosenson, Robert S., et al.
Publicado: (2010)

The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism()()
por: Huang, Jianfeng, et al.
Publicado: (2013)

The lipid-lowering drug fenofibrate combined with si-HOTAIR can effectively inhibit the proliferation of gliomas
por: Zhu, Wei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gsr9ttqise7n73nnblvofcjf90